Ipilimumab vs Nivolumab
Ipilimumab vs Nivolumab: Overview
This comparison examines the pharmacological differences between Ipilimumab and Nivolumab.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days; Nivolumab — 27 days.
Chemical Properties
Type: Ipilimumab — Antibody; Nivolumab — Antibody.